News

Promising treatments in oncology : Gustave Roussy is at the ESMO TAT congress

Le congrès ESMO Targeted Anticancer Therapies (TAT), organisé annuellement en Europe depuis 2018, est un événement incontournable dans le champ des nouvelles cibles et des nouveaux agents anticancéreux prometteurs, notamment ceux en essais précoces de développement clinique.

Published on

Equipe de chercheurs

The ESMO Targeted Anticancer Therapies (TAT) congress, organized annually in Europe since 2018, is a major event in promising new targets and new agents in oncology, mostly the ones in early trials of clinical development.

Its 2024 edition, which occurs from February 26 to February 28 in Paris, is an opportunity to have an overview of the future of innovating treatments and early trials currently run globally. The ESMO TAT congress also allows academics and industrials to exchange on the latest breakthroughs in oncology.

This year, the discussions will focus on innovations in phase I trials, with breakthroughs in target and cell therapies, in immunotherapy, and molecular imagery. Discussions will also focus on methodological and regulatory issues.

Strong representation of Gustave Roussy and its early trials department

Equipe de chercheurs

Gustave Roussy, strongly committed to phase I clinical trials through its Department of Therapeutic Innovations and Early Trials (DITEP), actually run by Christophe Massard, MD, PhD, has historically played a role in the creation of ESMO TAT congresses.

Gustave Roussy’s DITEP is one of the biggest early trials centers in Europe and in the world. In 2023, 2 700 patients have been screened, and 450 are dosed in Phase I and Phase I-II every year. At the same time, more than 140 protocols are currently run and 10,000 patients have been or are enrolled in a precision medicine program.

During this 2024 edition, several of the Institute's physician-researchers are taking the floor to talk about the research and clinical trials carried out at Gustave Roussy.

  • Fabrice André, MD, Ph.D., head of the research at Gustave Roussy, moderates a discussion on the challenges of the new regulations in Europe.
  • Antoine Italiano, MD, PhD, head of the precision medicine program at Gustave Roussy, provides an update on the new pI3KCA inhibitors.
  • Sophie Postel-Vinay, MD, PhD, head of the EpiCure SIRIC, is a member of the scientific committee of TAT. She is a moderator during the session “Diving into hepatobiliary malignancies”.
  • Capucine Bladini, MD, an oncologist at the DITEP, talks about new EGFR/HER2 inhibitors and puts the results of two studies on new immunotherapies into perspective.
  • Antoine Hollebecque, MD, an oncologist at the DITEP, gives his perspective on the immunotherapies in liver cancers.
  • Barbara Pistilli, MD, head of the breast diseases committee at Gustave Roussy, presents the latest developments in conjugate antibodies in oncology.

 

 

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin